Updated November 2026 · By Joel Blackstock, LICSW-S
Therapy for fibromyalgia does not cure the condition, but it can change how much the pain runs a person’s life. In randomized trials, cognitive behavioral therapy, mindfulness- and acceptance-based therapy and emotional awareness and expression therapy produce small to moderate gains in symptoms, mood and function. They belong alongside exercise, the one treatment European guidelines recommend strongly, and ordinary medical care. None of them assumes the pain is imaginary.
The argument of this page is simple to state. Fibromyalgia pain is produced by a nervous system that has turned up its own volume, a process pain researchers call central sensitization. Trauma, chronic stress, poor sleep and the fear of pain are among the things that hold the volume up. Psychotherapy cannot repair damaged tissue, and fibromyalgia pain does not mainly come from damaged tissue. What therapy can do is work on the amplifiers. That is a real target and a limited one, and an honest account of treatment has to hold both facts.

What fibromyalgia is, and how the diagnosis changed
Fibromyalgia is chronic widespread pain that usually comes with fatigue, unrefreshing sleep, memory and concentration problems and low mood. Daniel Clauw, then director of the University of Michigan’s Chronic Pain and Fatigue Research Center, estimated in a 2014 JAMA review that it affects as much as 2 to 8 percent of the population. He concludes that effective treatment is now possible, which is not the same thing as a cure.1
The diagnosis has shifted. The American College of Rheumatology’s 1990 criteria required widespread pain plus tenderness at 11 or more of 18 tender points.2 In 2010 a committee led by Frederick Wolfe, with Clauw among its members, replaced the tender-point exam with a widespread pain index and a symptom severity scale covering fatigue, unrefreshing sleep and cognitive symptoms.3 A 2016 revision removed earlier, confusing language about diagnostic exclusions.4 Fibromyalgia can be diagnosed alongside arthritis or another rheumatic disease, so the diagnosis does not rule anything else out, and new or changing symptoms still deserve a medical workup.2
The picture of fibromyalgia as a women’s illness also needs correcting. Clinic samples are overwhelmingly female: 93.9 percent in one German multicenter study.5 But when Wolfe and colleagues applied the 2010 criteria to a random sample of 2,445 German adults, prevalence was 2.4 percent in women and 1.8 percent in men, a difference that was not statistically significant. The authors found smooth, continuous relationships between overall symptom burden and every measure they examined, and read this as evidence that fibromyalgia is a dimensional or continuum disorder rather than a discrete disease.6
The pain is real: central sensitization and nociplastic pain
“It’s all in your head” has hurt a lot of people with fibromyalgia, and the research does not support it. In 2002 Richard Gracely, Clauw and colleagues scanned 16 patients and 16 matched controls with fMRI while pressing on their thumbnails. The pressure that gave patients moderate pain activated only two brain regions in the controls; at equal pressure, 13 regions were more active in patients. When the researchers raised the pressure on controls until they reported comparable pain, the two groups’ brain activity looked alike.7 Their nervous systems registered the same stimulus as more painful, and their reports matched what their brains were doing.
The underlying process is central sensitization. Clifford Woolf, the Harvard neurobiologist whose 1983 animal experiments showed that pain hypersensitivity after injury arises partly in the spinal cord,8 defines it as a prolonged but reversible increase in the excitability and synaptic efficacy of neurons in central pain pathways, and he lists fibromyalgia among the conditions to which it appears to contribute.9 Two words in that definition matter for therapy. “Central” means the amplification happens in the spinal cord and brain, not in the muscles that hurt. “Reversible” means it is a changed operating state, not a fixed injury.
In 2016 a group led by Eva Kosek asked whether pain science needed a third category alongside nociceptive pain, from tissue damage or inflammation, and neuropathic pain, from nerve damage.10 The field’s answer is nociplastic pain. A 2021 Lancet review by Mary-Ann Fitzcharles, Clauw and colleagues describes it as pain more widespread or intense than identifiable damage would predict, driven by augmented central processing and altered pain modulation, and usually accompanied by fatigue and sleep, memory and mood problems. It often occurs on its own in fibromyalgia, and it responds poorly to treatments aimed at the periphery, such as anti-inflammatory drugs, opioids, surgery and injections.11
Central amplification is not the whole story. Kathleen Sluka and Clauw describe fibromyalgia as heterogeneous, with patients falling along a continuum from mainly peripheral to mainly central drivers, and they name stress as one of the factors that can enhance the pain.12 A 2019 meta-analysis pooling eight small studies (222 participants) estimated that about 49 percent of people with fibromyalgia show small fiber pathology, abnormalities of thin nerve fibers seen in skin biopsies or the cornea.13 In 2021 a team led by Andreas Goebel gave mice antibodies (IgG) from fibromyalgia patients; the mice became more sensitive to pressure and cold, while IgG from healthy people had no effect.14 That is an animal experiment, not a treatment, but it is hard to square with the idea that fibromyalgia is purely psychological.
Fibromyalgia, then, is a real disorder of pain processing, with central amplification at its core and a set of inputs (sleep, stress, mood, threat) that turn the amplification up or down. Those inputs are where psychotherapy works.
Where trauma and chronic stress come in
The link between adversity and fibromyalgia is one of the more consistent findings in this literature, and one of the easiest to misuse. A 2011 meta-analysis by Winfried Häuser and colleagues pooled 18 case-control studies with 13,095 participants: people with fibromyalgia were more likely to report physical abuse (odds ratio 2.49) and sexual abuse (odds ratio 1.94) in childhood, though study quality was mostly poor.15 A 2014 meta-analysis of 71 studies found that people reporting trauma had 2.7 times the odds of a functional somatic syndrome such as fibromyalgia, with a larger association for PTSD than for abuse.16 A 2021 meta-analysis of 19 studies found associations for every type of stressor examined, strongest for physical abuse (odds ratio 3.23).17 A 2018 review of 51 studies found that most linked earlier physically traumatic events to the onset of fibromyalgia, on evidence it rated low in quality.18
PTSD is strikingly common. In Häuser’s 2013 study of 395 patients, 45.3 percent met criteria for PTSD, against 3.0 percent of matched people from the general population. In 66.5 percent the worst traumatic experience and the PTSD symptoms came before the chronic widespread pain; in 29.5 percent they came after it.5
Three cautions keep these numbers honest. First, nearly all of this research relies on people’s reports of their past, so it shows association, not cause. Second, an odds ratio of 2 or 3 describes a raised risk, not a requirement: most people who were abused never develop fibromyalgia, more than half of Häuser’s patients did not have PTSD, and Kaleycheva and colleagues concluded that stressors are likely one of many risk factors.17 Third, the arrow runs both ways. Häuser’s team concluded that PTSD and fibromyalgia are each potential risk factors for the other and can grow from the same earlier experiences.5 Years of unexplained pain, disbelief and lost work are a chronic stressor in their own right.
Why would adversity show up as pain? The most plausible route runs through the same amplification system. The Tel Aviv group that has tested neurofeedback in fibromyalgia starts from the premise that the condition’s sleep disturbance and emotion dysregulation amplify pain and are mediated by heightened limbic activity, the threat circuitry that includes the amygdala.19 This does not mean trauma causes fibromyalgia. It means trauma is one of the things that can keep the volume turned up, which is something therapy can act on. Our piece on the unconscious ways childhood trauma still shapes adult life describes how early experience persists without being remembered as a story.
What the treatment trials actually show
The main lesson of fibromyalgia treatment research is modesty. The 2017 European League Against Rheumatism (EULAR) recommendations, built on 107 systematic reviews and meta-analyses, gave only one therapy a “strong for” rating: exercise. The psychological therapies, selected drugs and multimodal rehabilitation it recommended were rated “weak for,” and the authors wrote that the size of effect for most treatments is relatively modest. Their stepped approach, which they based on expert opinion, starts with education and non-drug therapies, then adds psychological therapy for mood problems and unhelpful coping, medication for severe pain or sleep disturbance, and rehabilitation for severe disability.20
Even exercise helps only modestly. A 2017 Cochrane review of aerobic exercise (13 trials, 839 people) concluded that, compared with no exercise, it may slightly reduce pain, by about 11 points on a 100-point scale, on low-quality evidence.21 Exercise is also hard to start when activity brings flares. A review led by Jo Nijs found fear of movement and avoidance of activity highly prevalent in fibromyalgia, tied to symptom severity and disability, and judged individually tailored CBT combined with exercise the most promising way to treat it.22
Cognitive behavioral therapy is the most studied psychological treatment. A 2018 meta-analysis by Kathrin Bernardy and colleagues (29 trials, 2,509 people) found that CBT beat control conditions on 50 percent pain relief, but by a risk difference of 0.05, about five additional people in every hundred. Effects on negative mood, disability and fatigue were small to moderate, and the authors judged CBT as effective as the recommended drugs, pregabalin and duloxetine, while better tolerated and better for coping with pain.23 A 2022 meta-analysis of 167 trials found that psychological treatments, including CBT and mindfulness, improved pain, sleep, depression and overall fibromyalgia impact, but not fatigue.24 Mindfulness- and acceptance-based therapies show small to moderate effects that a 2019 review called promising but uncertain.25 For how these approaches relate, see our guide to how the different types of therapy fit together.
The trial that best fits this page’s argument came from Wayne State University and the University of Michigan in 2017. Mark Lumley, Howard Schubiner, Clauw, David Williams and colleagues started from the observation that people with fibromyalgia carry higher lifetime levels of adversity, trauma and emotional conflict. The 230 adults formed 40 groups, which were randomized to eight 90-minute sessions of fibromyalgia education, standard CBT, or emotional awareness and expression therapy (EAET), which targets emotions tied to adversity and conflict. At six months, EAET did not beat education on pain severity, the primary outcome. It did beat education on overall symptoms, widespread pain, physical functioning, anxiety, depression and several other outcomes, and 34.8 percent of EAET patients rated themselves much or very much improved, against 15.4 percent after education. EAET did not differ from CBT on the primary outcome or most secondary ones, but it produced lower overall fibromyalgia symptoms and less widespread pain, and more patients reached a 50 percent pain reduction: 22.5 percent against 8.3 percent.26
Those numbers cut both ways. Working directly on avoided emotion and old adversity beat education on several outcomes and edged out CBT on a few pain measures, which fits the idea that trauma and conflict feed the amplification. The same treatment missed its primary outcome against an education class, and more than three in four EAET patients did not get a 50 percent drop in pain. That is what a real effect in fibromyalgia looks like.
Medication belongs in the same frame. A 2025 overview of 21 Cochrane reviews (87 trials, 17,631 patients) found good evidence for three drugs, duloxetine, milnacipran and pregabalin, all FDA-approved for fibromyalgia. Each gave a pain reduction of at least 50 percent to about one person in ten with moderate or severe pain over 4 to 12 weeks, with no evidence of efficacy beyond six months; most other drugs lacked usable evidence of benefit.27 Decisions about starting, stopping or combining medication belong with your prescriber, and that conversation is worth having alongside therapy, not instead of it.
EMDR, Somatic Experiencing, Brainspotting and neurofeedback: an honest scorecard
Trauma-focused and body-based therapies are a large part of what we do at Taproot. Their evidence in fibromyalgia is thinner than CBT’s, and the earlier version of this page overstated it.
EMDR. We found one published randomized trial in fibromyalgia. In 2024 Zat Çiftçi and colleagues in Turkey assigned 79 patients to usual care or usual care plus up to 15 sessions of EMDR; 64 were analyzed. The EMDR group did better on pain ratings, the widespread pain index, depression and trauma symptoms, but not on total Fibromyalgia Impact Questionnaire scores. The outcomes were self-report scales, a limitation the authors acknowledge, and a usual-care comparison cannot separate EMDR from the effect of extra attention.28 The authors call this robust evidence; one small trial against usual care is a promising start. A Dutch single-case study of ten women found pain fell significantly in six after six sessions, with three keeping the gain at three months.29 Our review of whether EMDR is evidence-based covers what is established for PTSD.
Somatic Experiencing. The earlier version of this page cited a 2021 randomized trial of Somatic Experiencing for fibromyalgia. It does not exist; the journal volume and page it listed belong to a paper on rhabdomyosarcoma. The closest real evidence is a Danish trial of 91 patients with chronic low back pain and PTSD. Adding 6 to 12 sessions of SE to exercise-based care reduced PTSD symptoms and fear of movement, but pain and disability improved in both groups, and the authors judged the overall effect less than expected.30 Fear of movement matters in fibromyalgia, so the result is relevant, but it is not a fibromyalgia trial. The method is explained in our piece on Somatic Experiencing as a mind-body approach.
Brainspotting. The peer-reviewed literature is thin and largely theoretical; its central paper, by Frank Corrigan and Brainspotting’s developer David Grand, is a hypothesis paper proposing a midbrain mechanism.31 We found no controlled trials of Brainspotting for fibromyalgia or chronic pain. The earlier claim that it releases stored trauma at a deep subcortical level is a hypothesis, not a finding.
Neurofeedback. Two small trials from Tel Aviv used a protocol in which patients learn to turn down an EEG signal modeled on amygdala activity. In the first, with 34 patients, real training improved objective sleep measures; self-reported symptoms did not differ at the end of treatment, and pain improved later, at follow-up.19 In the second, 47 patients received real training, sham training or usual care. Real training reduced symptom severity and fibromyalgia impact, with benefits at 10 to 12 months; sham training also reduced pain over the long term.32 The trials are small and test one specialized protocol, so the results do not automatically carry over to other neurofeedback. If you are considering brain mapping and neurofeedback, ask how the protocol you would receive compares with what was tested.
Pain reprocessing therapy. The most striking recent result comes from chronic back pain. In a 2022 trial led by Yoni Ashar, with 151 adults whose pain was on average mild to moderate, 66 percent of people given pain reprocessing therapy were pain-free or nearly so after treatment, against 20 percent given an open-label placebo injection and 10 percent in usual care.33 PRT teaches people to reappraise pain as a non-dangerous brain signal; Schubiner and Lumley were among the trial’s authors. In fibromyalgia the only published study we found is a three-session telehealth pilot with no control group, in which 42.3 percent of completers reported being much or very much improved at three months.34 A randomized trial is still needed. We describe the method in pain reprocessing therapy and the brain’s response to chronic pain.
Stigma, story and the temptation to read pain as a symbol
Fibromyalgia is a contested illness, one whose reality has been argued over by doctors, insurers and sometimes families; the sociologist Kristin Barker wrote a book-length study of that dispute.35 Erving Goffman’s 1963 Stigma described how people with a stigmatized difference manage others’ impressions through concealment and “passing,” blending in by not disclosing.36 In Armentor’s interviews with 20 women with fibromyalgia, disbelief often led them to avoid social contact to hide from the stigma.37 A 2025 meta-synthesis of 151 qualitative reports across contested and hard-to-diagnose conditions, fibromyalgia among them, found that having symptoms dismissed by clinicians led to shame, health care-related anxiety and trauma, avoidance of care and delayed diagnosis.38 That shame deserves treatment in its own right; our piece on the shame spiral and a somatic approach to toxic shame describes how it lives in the body.
Illness also has to be told as a story. Arthur Frank’s The Wounded Storyteller (1995) described three kinds of illness narrative: restitution, which expects a return to health; chaos, which has no order or progress; and quest, in which the illness becomes a journey that yields something.39 A British study of 17 people with chronic fatigue syndrome, another contested condition, found them moving from restitution into chaos and, for most, back toward restitution and on to quest.40 The quest story has the shape of Joseph Campbell’s hero’s journey,41 and the earlier version of this page leaned on it hard. It is a useful story when a patient arrives at it. It is a cruel one when it is handed to someone in the middle of chaos as a promise that suffering will turn into wisdom.
Depth psychology has its own version of this risk. Its tradition, from early psychosomatic medicine to Arnold Mindell’s work on what he called the dreaming body, tends to read physical symptoms as messages from the psyche.42 With fibromyalgia, decoding the pain as a symbol repeats the “it’s psychological” dismissal in more flattering language. The more useful idea is Jung’s shadow: the feelings and parts of ourselves we have learned not to see.43 Anger at a body that no longer cooperates, grief for a former life, rage at old abuse and resentment of the people who did not believe you are often present and often unspoken. EAET works on much the same material in a structured, testable form, and it is the version with data behind it. Our essay on the Jungian shadow explains the concept.
What this looks like in therapy
Good therapy for fibromyalgia starts by treating the pain as real and the diagnosis as medical. Early sessions cover the pain history alongside the life history: when symptoms started and what was happening then, what makes them flare, how sleep is going, and how clinicians have treated the person. New or changing symptoms that nobody has evaluated call for a medical visit first. We would rather coordinate with your physician or rheumatologist than work around them.
From there, the work usually follows the amplifiers:
- Threat and fear of pain. Learning the difference between hurt and harm, and returning to avoided movement at a pace the nervous system can tolerate. This is where CBT, acceptance-based work and pain reprocessing overlap.
- Sleep. Poor sleep is part of the syndrome and appears to feed the pain.19 Behavioral sleep work belongs in the plan, and so does a conversation with a physician.
- Avoided emotion. Grief over lost function, anger, and the residue of being disbelieved. This is the territory EAET tested, and where parts-based and depth work fits.
- Trauma, when it is there. For someone with PTSD or a significant trauma history, EMDR or a somatic approach can be part of treatment. The target is the trauma symptoms and the arousal they keep alive; any change in pain is a possible benefit, not a promise.
- Pacing and meaning. Building a life that fits the body you have now, without waiting for restitution and without pretending the losses are gifts.
Central sensitization also shows up beyond fibromyalgia. In a 2026 study of 305 patients with postural orthostatic tachycardia syndrome (POTS), 86.6 percent met questionnaire criteria for central sensitization, and fibromyalgia was more common among them than among the rest.44 Our piece on POTS and dysautonomia from a mind-body perspective covers the autonomic side.
What therapy cannot honestly promise is the end of fibromyalgia. The trials support something smaller and still worth having: a minority of patients get large reductions in pain, and a larger share get meaningful improvement in mood, function and how much the pain dictates their days.
If you live in Alabama and want help with fibromyalgia or another chronic pain condition alongside your medical care, our page on therapy for chronic pain and chronic illness in Hoover explains how we approach it and how to reach us.
References
- Clauw, D. J. (2014). Fibromyalgia: A clinical review. JAMA, 311(15), 1547–1555. https://doi.org/10.1001/jama.2014.3266
- Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., Fam, A. G., Farber, S. J., Fiechtner, J. J., Franklin, C. M., Gatter, R. A., Hamaty, D., Lessard, J., Lichtbroun, A. S., Masi, A. T., . . . Sheon, R. P. (1990). The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis & Rheumatism, 33(2), 160–172. https://doi.org/10.1002/art.1780330203
- Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010). The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research, 62(5), 600–610. https://doi.org/10.1002/acr.20140
- Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Häuser, W., Katz, R. L., Mease, P. J., Russell, A. S., Russell, I. J., & Walitt, B. (2016). 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism, 46(3), 319–329. https://doi.org/10.1016/j.semarthrit.2016.08.012
- Häuser, W., Galek, A., Erbslöh-Möller, B., Köllner, V., Kühn-Becker, H., Langhorst, J., Petermann, F., Prothmann, U., Winkelmann, A., Schmutzer, G., Brähler, E., & Glaesmer, H. (2013). Posttraumatic stress disorder in fibromyalgia syndrome: Prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain, 154(8), 1216–1223. https://doi.org/10.1016/j.pain.2013.03.034
- Wolfe, F., Brähler, E., Hinz, A., & Häuser, W. (2013). Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: Results from a survey of the general population. Arthritis Care & Research, 65(5), 777–785. https://doi.org/10.1002/acr.21931
- Gracely, R. H., Petzke, F., Wolf, J. M., & Clauw, D. J. (2002). Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis & Rheumatism, 46(5), 1333–1343. https://doi.org/10.1002/art.10225
- Woolf, C. J. (1983). Evidence for a central component of post-injury pain hypersensitivity. Nature, 306(5944), 686–688. https://doi.org/10.1038/306686a0
- Woolf, C. J. (2011). Central sensitization: Implications for the diagnosis and treatment of pain. Pain, 152(3 Suppl.), S2–S15. https://doi.org/10.1016/j.pain.2010.09.030
- Kosek, E., Cohen, M., Baron, R., Gebhart, G. F., Mico, J.-A., Rice, A. S. C., Rief, W., & Sluka, A. K. (2016). Do we need a third mechanistic descriptor for chronic pain states? Pain, 157(7), 1382–1386. https://doi.org/10.1097/j.pain.0000000000000507
- Fitzcharles, M.-A., Cohen, S. P., Clauw, D. J., Littlejohn, G., Usui, C., & Häuser, W. (2021). Nociplastic pain: Towards an understanding of prevalent pain conditions. The Lancet, 397(10289), 2098–2110. https://doi.org/10.1016/S0140-6736(21)00392-5
- Sluka, K. A., & Clauw, D. J. (2016). Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience, 338, 114–129. https://doi.org/10.1016/j.neuroscience.2016.06.006
- Grayston, R., Czanner, G., Elhadd, K., Goebel, A., Frank, B., Üçeyler, N., Malik, R. A., & Alam, U. (2019). A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. Seminars in Arthritis and Rheumatism, 48(5), 933–940. https://doi.org/10.1016/j.semarthrit.2018.08.003
- Goebel, A., Krock, E., Gentry, C., Israel, M. R., Jurczak, A., Urbina, C. M., Sandor, K., Vastani, N., Maurer, M., Cuhadar, U., Sensi, S., Nomura, Y., Menezes, J., Baharpoor, A., Brieskorn, L., Sandström, A., Tour, J., Kadetoff, D., Haglund, L., . . . Andersson, D. A. (2021). Passive transfer of fibromyalgia symptoms from patients to mice. Journal of Clinical Investigation, 131(13), Article e144201. https://doi.org/10.1172/JCI144201
- Häuser, W., Kosseva, M., Üceyler, N., Klose, P., & Sommer, C. (2011). Emotional, physical, and sexual abuse in fibromyalgia syndrome: A systematic review with meta-analysis. Arthritis Care & Research, 63(6), 808–820. https://doi.org/10.1002/acr.20328
- Afari, N., Ahumada, S. M., Wright, L. J., Mostoufi, S., Golnari, G., Reis, V., & Cuneo, J. G. (2014). Psychological trauma and functional somatic syndromes: A systematic review and meta-analysis. Psychosomatic Medicine, 76(1), 2–11. https://doi.org/10.1097/PSY.0000000000000010
- Kaleycheva, N., Cullen, A. E., Evans, R., Harris, T., Nicholson, T., & Chalder, T. (2021). The role of lifetime stressors in adult fibromyalgia: Systematic review and meta-analysis of case-control studies. Psychological Medicine, 51(2), 177–193. https://doi.org/10.1017/S0033291720004547
- Yavne, Y., Amital, D., Watad, A., Tiosano, S., & Amital, H. (2018). A systematic review of precipitating physical and psychological traumatic events in the development of fibromyalgia. Seminars in Arthritis and Rheumatism, 48(1), 121–133. https://doi.org/10.1016/j.semarthrit.2017.12.011
- Goldway, N., Ablin, J., Lubin, O., Zamir, Y., Keynan, J. N., Or-Borichev, A., Cavazza, M., Charles, F., Intrator, N., Brill, S., Ben-Simon, E., Sharon, H., & Hendler, T. (2019). Volitional limbic neuromodulation exerts a beneficial clinical effect on fibromyalgia. NeuroImage, 186, 758–770. https://doi.org/10.1016/j.neuroimage.2018.11.001
- Macfarlane, G. J., Kronisch, C., Dean, L. E., Atzeni, F., Häuser, W., Fluß, E., Choy, E., Kosek, E., Amris, K., Branco, J., Dincer, F., Leino-Arjas, P., Longley, K., McCarthy, G. M., Makri, S., Perrot, S., Sarzi-Puttini, P., Taylor, A., & Jones, G. T. (2017). EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases, 76(2), 318–328. https://doi.org/10.1136/annrheumdis-2016-209724
- Bidonde, J., Busch, A. J., Schachter, C. L., Overend, T. J., Kim, S. Y., Góes, S. M., Boden, C., & Foulds, H. J. (2017). Aerobic exercise training for adults with fibromyalgia. Cochrane Database of Systematic Reviews, 2017(6), Article CD012700. https://doi.org/10.1002/14651858.CD012700
- Nijs, J., Roussel, N., Van Oosterwijck, J., De Kooning, M., Ickmans, K., Struyf, F., Meeus, M., & Lundberg, M. (2013). Fear of movement and avoidance behaviour toward physical activity in chronic-fatigue syndrome and fibromyalgia: State of the art and implications for clinical practice. Clinical Rheumatology, 32(8), 1121–1129. https://doi.org/10.1007/s10067-013-2277-4
- Bernardy, K., Klose, P., Welsch, P., & Häuser, W. (2018). Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome: A systematic review and meta-analysis of randomized controlled trials. European Journal of Pain, 22(2), 242–260. https://doi.org/10.1002/ejp.1121
- Kundakci, B., Kaur, J., Goh, S. L., Hall, M., Doherty, M., Zhang, W., & Abhishek, A. (2022). Efficacy of nonpharmacological interventions for individual features of fibromyalgia: A systematic review and meta-analysis of randomised controlled trials. Pain, 163(8), 1432–1445. https://doi.org/10.1097/j.pain.0000000000002500
- Haugmark, T., Hagen, K. B., Smedslund, G., & Zangi, H. A. (2019). Mindfulness- and acceptance-based interventions for patients with fibromyalgia: A systematic review and meta-analyses. PLOS ONE, 14(9), Article e0221897. https://doi.org/10.1371/journal.pone.0221897
- Lumley, M. A., Schubiner, H., Lockhart, N. A., Kidwell, K. M., Harte, S. E., Clauw, D. J., & Williams, D. A. (2017). Emotional awareness and expression therapy, cognitive behavioral therapy, and education for fibromyalgia: A cluster-randomized controlled trial. Pain, 158(12), 2354–2363. https://doi.org/10.1097/j.pain.0000000000001036
- Moore, A., Bidonde, J., Fisher, E., Häuser, W., Bell, R. F., Perrot, S., Makri, S., & Straube, S. (2025). Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: An overview of Cochrane Reviews. Rheumatology, 64(5), 2385–2394. https://doi.org/10.1093/rheumatology/keae707
- Zat Çiftçi, Z., Delibaş, D. H., Kaya, T., Külcü, D. G., Sarı, A., Nazlıkul, H., Coşkun Topsakal, İ., Aydın, Y. E., Kavakçı, Ö., Savran, C., & Konuk, E. (2024). A randomized controlled trial of eye movement desensitization and reprocessing (EMDR) therapy in the treatment of fibromyalgia. Frontiers in Psychiatry, 15, Article 1286118. https://doi.org/10.3389/fpsyt.2024.1286118
- Borst, M., Moeyaert, M., & van Rood, Y. (2024). The effect of eye movement desensitization and reprocessing on fibromyalgia: A multiple-baseline experimental case study across ten participants. Neuropsychological Rehabilitation, 34(10), 1422–1454. https://doi.org/10.1080/09602011.2024.2314883
- Andersen, T. E., Lahav, Y., Ellegaard, H., & Manniche, C. (2017). A randomized controlled trial of brief Somatic Experiencing for chronic low back pain and comorbid post-traumatic stress disorder symptoms. European Journal of Psychotraumatology, 8(1), Article 1331108. https://doi.org/10.1080/20008198.2017.1331108
- Corrigan, F., & Grand, D. (2013). Brainspotting: Recruiting the midbrain for accessing and healing sensorimotor memories of traumatic activation. Medical Hypotheses, 80(6), 759–766. https://doi.org/10.1016/j.mehy.2013.03.005
- Or-Borichev, A., Lerner, Y., Hamrani, Y., Gurevitch, G., Mor, N., Doron, M., Sarna, N., Ablin, J. N., Hendler, T., & Sharon, H. (2025). Targeted limbic self-neuromodulation for alleviating central sensitization symptoms in fibromyalgia. BMC Medicine, 23(1), Article 304. https://doi.org/10.1186/s12916-025-04138-3
- Ashar, Y. K., Gordon, A., Schubiner, H., Uipi, C., Knight, K., Anderson, Z., Carlisle, J., Polisky, L., Geuter, S., Flood, T. F., Kragel, P. A., Dimidjian, S., Lumley, M. A., & Wager, T. D. (2022). Effect of pain reprocessing therapy vs placebo and usual care for patients with chronic back pain: A randomized clinical trial. JAMA Psychiatry, 79(1), 13–23. https://doi.org/10.1001/jamapsychiatry.2021.2669
- Sturgeon, J., Trost, Z., Ashar, Y. K., Lumley, M. A., Schubiner, H., Clauw, D., & Hassett, A. L. (2025). Brief pain reprocessing therapy for fibromyalgia: A feasibility, acceptability, and preliminary efficacy pilot. Regional Anesthesia & Pain Medicine. Advance online publication. https://doi.org/10.1136/rapm-2025-107076
- Barker, K. K. (2005). The fibromyalgia story: Medical authority and women’s worlds of pain. Temple University Press.
- Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. Prentice-Hall.
- Armentor, J. L. (2017). Living with a contested, stigmatized illness: Experiences of managing relationships among women with fibromyalgia. Qualitative Health Research, 27(4), 462–473. https://doi.org/10.1177/1049732315620160
- Bontempo, A. C., Bontempo, J. M., & Duberstein, P. R. (2025). Ignored, dismissed, and minimized: Understanding the harmful consequences of invalidation in health care—A systematic meta-synthesis of qualitative research. Psychological Bulletin, 151(4), 399–427. https://doi.org/10.1037/bul0000473
- Frank, A. W. (1995). The wounded storyteller: Body, illness, and ethics. University of Chicago Press. https://doi.org/10.7208/chicago/9780226260037.001.0001
- Whitehead, L. C. (2006). Quest, chaos and restitution: Living with chronic fatigue syndrome/myalgic encephalomyelitis. Social Science & Medicine, 62(9), 2236–2245. https://doi.org/10.1016/j.socscimed.2005.09.008
- Campbell, J. (1949). The hero with a thousand faces. Pantheon Books.
- Mindell, A. (1986). Working with the dreaming body. Routledge & Kegan Paul.
- Jung, C. G. (1959). Aion: Researches into the phenomenology of the self (R. F. C. Hull, Trans.; Collected Works of C. G. Jung, Vol. 9, Pt. 2). Pantheon Books.
- Mathew, G. T., & Novak, P. (2026). Prevalence of central sensitization in postural tachycardia syndrome. JAMA Network Open, 9(1), Article e2553694. https://doi.org/10.1001/jamanetworkopen.2025.53694


























0 Comments